Surface Oncology, Inc. (SURF) News

Surface Oncology, Inc. (SURF): $7.23

-0.32 (-4.24%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter SURF News Items

SURF News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

SURF News Highlights

  • SURF's 30 day story count now stands at 2.
  • Over the past 7 days, the trend for SURF's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • The most mentioned tickers in articles about SURF are AFMD, DZSI and ES.

Latest SURF News From Around the Web

Below are the latest news stories about Surface Oncology Inc that investors may wish to consider to help them evaluate SURF as an investment opportunity.

Why AstraZeneca and Surface Oncology Rose Today

The pharmaceutical giant reports encouraging results from a late-stage ES-SCLC trial of blockbuster cancer treatment Imfinzi.

Yahoo | September 20, 2021

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

There's only one day of trading left so let's start it off right with a look at the biggest pre-market stock movers for Friday.

William White on InvestorPlace | September 17, 2021

New Strong Sell Stocks for September 13th

AFMD, DZSI, GMBL, NTRB, and SURF have been added to the Zacks Rank #5 (Strong Sell) List on September 13, 2021.

Yahoo | September 13, 2021

What Is The Ownership Structure Like For Surface Oncology, Inc. (NASDAQ:SURF)?

The big shareholder groups in Surface Oncology, Inc. ( NASDAQ:SURF ) have power over the company. Institutions often...

Yahoo | August 23, 2021

Surface Oncology Reports Financial Results and Corporate Highlights for Second Quarter 2021

SRF388, a First-in-Class Anti-IL-27 Antibody, Demonstrates Monotherapy Activity in Ongoing Phase 1 Study; Enrollment Continues for Phase 2 Monotherapy Expansion and Combination Cohorts SRF617, a CD39 Inhibitor, Demonstrates Good Tolerability in Ongoing Phase 1 Study; Phase 2 Dose Confirmed and Enrollment Continues for Combination Cohorts CAMBRIDGE, Mass., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunot

Yahoo | August 5, 2021

Surface Oncology's (NASDAQ:SURF) Shareholders Are Down 58% On Their Shares

Investing in stocks inevitably means buying into some companies that perform poorly. Long term Surface Oncology, Inc...

Yahoo | July 8, 2021

Surface Oncology Appoints Denice Torres to Board of Directors

Brings 25 years of strategic leadership experience across healthcareCAMBRIDGE, Mass., July 08, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Denice Torres will join the company’s board of directors. Ms. Torres has over 25 years of executive leadership experience in healthcare across the consumer, biopharmaceutical and medical device sectors.

Yahoo | July 8, 2021

Could Surface Oncology Be a Millionaire-Maker Stock?

Investors looking for a shot at big gains from this clinical-stage biotech will need to be comfortable with making a speculative buy.

Yahoo | May 16, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.6999 seconds.